Navigation Links
Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
Date:3/7/2011

VANCOUVER, British Columbia, March 7, 2011 /PRNewswire/ -- Allon Therapeutics Inc. (TSX: NPC), today announced that their March 3rd RetailInvestorConferences.com presentation is available for on-demand viewing.

LINK: www.retailinvestorconferences.com Click the red "register/ watch events now" button.

Allon Therapeutics' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Allon Therapeutics Inc.:

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon's lead drug davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under an SPA with the FDA. This pivotal trial is based upon statistically significant human efficacy demonstrated in amnestic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" and based in Vancouver.

For additional information please visit the company's website: www.allontherapeutics.com

About RetailInvestorConferences.com:

RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Forward-Looking Statements:

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at www.SEDAR.com and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.


'/>"/>
SOURCE Allon Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
2. Allon Therapeutics to Present Live, Online at RetailInvestorConferences.com on March 3rd
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):